Free tool
FAERS Monitor: Zilxi
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 213690 or its brand name (Zilxi, Minocycline Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
11,615
Serious
8,929
77% of reports
Hospitalization
3,776
Death reported
1,645
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective1,974
- off label use1,482
- nausea1,075
- pain1,019
- arthralgia1,001
- fatigue957
- drug intolerance913
- rash909
- drug hypersensitivity908
- rheumatoid arthritis879
- joint swelling873
- headache802
- condition aggravated753
- diarrhoea751
- pneumonia749
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 11 |
| 2005 | 52 |
| 2006 | 7 |
| 2007 | 2 |
| 2008 | 6 |
| 2009 | 79 |
| 2010 | 86 |
| 2011 | 99 |
| 2012 | 233 |
| 2013 | 416 |
| 2014 | 431 |
| 2015 | 539 |
| 2016 | 806 |
| 2017 | 871 |
| 2018 | 894 |
| 2019 | 1,143 |
| 2020 | 1,001 |
| 2021 | 762 |
| 2022 | 695 |
| 2023 | 877 |
| 2024 | 1,202 |
| 2025 | 966 |
| 2026 | 437 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,042,544 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| drug intoleranceSignal | 913 | 17.3 | 16.2 | 13,908 |
| rheumatoid arthritisSignal | 879 | 14.1 | 13.2 | 10,679 |
| joint swellingSignal | 873 | 13.2 | 12.4 | 9,803 |
| drug hypersensitivitySignal | 908 | 8.5 | 8.0 | 6,057 |
| condition aggravatedSignal | 753 | 4.5 | 4.2 | 2,067 |
| arthralgiaSignal | 1,001 | 4.4 | 4.1 | 2,642 |
| pneumoniaSignal | 749 | 4.2 | 3.9 | 1,845 |
| rashSignal | 909 | 3.8 | 3.6 | 1,893 |
| off label useSignal | 1,482 | 3.1 | 2.9 | 2,150 |
| painSignal | 1,019 | 3.0 | 2.8 | 1,402 |
| drug ineffectiveSignal | 1,974 | 2.7 | 2.6 | 2,276 |
| nauseaSignal | 1,075 | 2.5 | 2.3 | 967 |
| headacheSignal | 802 | 2.3 | 2.2 | 617 |
| fatigueSignal | 957 | 2.2 | 2.1 | 670 |
| diarrhoeaSignal | 751 | 2.1 | 2.0 | 450 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.